159 related articles for article (PubMed ID: 23919066)
1. Detecting primary bladder cancer using delayed (18)F-2-fluoro-2-deoxy-D-glucose-positron emission tomography/computed tomography imaging after forced diuresis.
Mertens LS; Fioole-Bruining A; Vegt E; Vogel WV; van Rhijn BW; Horenblas S
Indian J Nucl Med; 2012 Jul; 27(3):145-50. PubMed ID: 23919066
[TBL] [Abstract][Full Text] [Related]
2. Forced diuresis and dual-phase F-fluorodeoxyglucose-PET/CT scan for restaging of urinary bladder cancers.
Harkirat S; Anand S; Jacob M
Indian J Radiol Imaging; 2010 Feb; 20(1):13-9. PubMed ID: 20351986
[TBL] [Abstract][Full Text] [Related]
3.
Wang HC; Wang ZM; Wang YB; Chen XH; Cui LL
Abdom Radiol (NY); 2017 May; 42(5):1415-1423. PubMed ID: 28028557
[TBL] [Abstract][Full Text] [Related]
4. More advantages in detecting bone and soft tissue metastases from prostate cancer using
Pianou NK; Stavrou PZ; Vlontzou E; Rondogianni P; Exarhos DN; Datseris IE
Hell J Nucl Med; 2019; 22(1):6-9. PubMed ID: 30843003
[TBL] [Abstract][Full Text] [Related]
5. Dual phase 18F-fluorodeoxyglucose positron emission tomography/computed tomography with forced diuresis in diagnostic imaging evaluation of bladder cancer.
Yildirim-Poyraz N; Ozdemir E; Uzun B; Turkolmez S
Rev Esp Med Nucl Imagen Mol; 2013; 32(4):214-21. PubMed ID: 23218514
[TBL] [Abstract][Full Text] [Related]
6. Diuretic 18F-FDG PET/CT imaging for detection and locoregional staging of urinary bladder cancer: prospective evaluation of a novel technique.
Nayak B; Dogra PN; Naswa N; Kumar R
Eur J Nucl Med Mol Imaging; 2013 Feb; 40(3):386-93. PubMed ID: 23179944
[TBL] [Abstract][Full Text] [Related]
7. Detectability of residual invasive bladder cancer in delayed
Higashiyama A; Komori T; Juri H; Inada Y; Azuma H; Narumi Y
Ann Nucl Med; 2018 Oct; 32(8):561-567. PubMed ID: 30014439
[TBL] [Abstract][Full Text] [Related]
8. Clinical Relevance of Incidental Prostatic Lesions on FDG-Positron Emission Tomography/Computerized Tomography-Should Patients Receive Further Evaluation?
Reesink DJ; Fransen van de Putte EE; Vegt E; De Jong J; van Werkhoven E; Mertens LS; Bex A; van der Poel HG; van Rhijn BW; Horenblas S; Meijer RP
J Urol; 2016 Apr; 195(4 Pt 1):907-12. PubMed ID: 26598424
[TBL] [Abstract][Full Text] [Related]
9. 18F-FDG PET/CT delayed images after diuretic for restaging invasive bladder cancer.
Anjos DA; Etchebehere EC; Ramos CD; Santos AO; Albertotti C; Camargo EE
J Nucl Med; 2007 May; 48(5):764-70. PubMed ID: 17475965
[TBL] [Abstract][Full Text] [Related]
10. Clinical value of fluorine-18 2-fluoro-2-deoxy-D-glucose positron emission tomography/computed tomography in bladder cancer.
Apolo AB; Riches J; Schöder H; Akin O; Trout A; Milowsky MI; Bajorin DF
J Clin Oncol; 2010 Sep; 28(25):3973-8. PubMed ID: 20679618
[TBL] [Abstract][Full Text] [Related]
11. Comparisons between glucose analogue 2-deoxy-2-((18)F)fluoro-D-glucose and (18)F-sodium fluoride positron emission tomography/computed tomography in breast cancer patients with bone lesions.
Capitanio S; Bongioanni F; Piccardo A; Campus C; Gonella R; Tixi L; Naseri M; Pennone M; Altrinetti V; Buschiazzo A; Bossert I; Fiz F; Bruno A; DeCensi A; Sambuceti G; Morbelli S
World J Radiol; 2016 Feb; 8(2):200-9. PubMed ID: 26981229
[TBL] [Abstract][Full Text] [Related]
12. Impact of 18F-FDG PET/CT with retrograde filling of the urinary bladder in patients with suspected pelvic malignancies.
Vicente AM; Castrejón AS; Muñoz AP; Woll PP; García AN
J Nucl Med Technol; 2010 Sep; 38(3):128-37. PubMed ID: 20807854
[TBL] [Abstract][Full Text] [Related]
13. Is whole-body fluorine-18 fluorodeoxyglucose PET/CT plus additional pelvic images (oral hydration-voiding-refilling) useful for detecting recurrent bladder cancer?
Yang Z; Cheng J; Pan L; Hu S; Xu J; Zhang Y; Wang M; Zhang J; Ye D; Zhang Y
Ann Nucl Med; 2012 Aug; 26(7):571-7. PubMed ID: 22763630
[TBL] [Abstract][Full Text] [Related]
14. Dual time point fluorodeoxyglucose positron emission tomography/computed tomography in differentiation between malignant and benign lesions in cancer patients. Does it always work?
Saleh Farghaly HR; Mohamed Sayed MH; Nasr HA; Abdelaziz Maklad AM
Indian J Nucl Med; 2015; 30(4):314-9. PubMed ID: 26430314
[TBL] [Abstract][Full Text] [Related]
15. Assessment of indeterminate pulmonary nodules detected in lung cancer screening: Diagnostic accuracy of FDG PET/CT.
Garcia-Velloso MJ; Bastarrika G; de-Torres JP; Lozano MD; Sanchez-Salcedo P; Sancho L; Nuñez-Cordoba JM; Campo A; Alcaide AB; Torre W; Richter JA; Zulueta JJ
Lung Cancer; 2016 Jul; 97():81-6. PubMed ID: 27237032
[TBL] [Abstract][Full Text] [Related]
16. Integrated analysis of
Girard A; Rouanne M; Taconet S; Radulescu C; Neuzillet Y; Girma A; Beaufrere A; Lebret T; Le Stanc E; Grellier JF
Eur Radiol; 2019 Aug; 29(8):4286-4293. PubMed ID: 30666449
[TBL] [Abstract][Full Text] [Related]
17. A prospective diagnostic accuracy study of F-18 fluorodeoxyglucose-positron emission tomography/computed tomography in the evaluation of indeterminate renal masses.
Ozülker T; Ozülker F; Ozbek E; Ozpaçaci T
Nucl Med Commun; 2011 Apr; 32(4):265-72. PubMed ID: 21301376
[TBL] [Abstract][Full Text] [Related]
18. [The role of whole body 2-[fluorine-18]-fluoro-2-deoxy-D-glucose positron emission tomography/computed tomography in the management of unknown primary tumors].
Wu ZJ; Zhang YX; Wei H; Jia Q
Zhonghua Yi Xue Za Zhi; 2007 Aug; 87(32):2253-6. PubMed ID: 18001544
[TBL] [Abstract][Full Text] [Related]
19. Preoperative lymph-node staging of invasive urothelial bladder cancer with 18F-fluorodeoxyglucose positron emission tomography/computed axial tomography and magnetic resonance imaging: correlation with histopathology.
Jensen TK; Holt P; Gerke O; Riehmann M; Svolgaard B; Marcussen N; Bouchelouche K
Scand J Urol Nephrol; 2011 Mar; 45(2):122-8. PubMed ID: 21231796
[TBL] [Abstract][Full Text] [Related]
20.
Parihar AS; Mittal BR; Kumar R; Shukla J; Bhattacharya A
Thyroid; 2020 Apr; 30(4):557-567. PubMed ID: 31870227
[No Abstract] [Full Text] [Related]
[Next] [New Search]
